Search
multiplex IMMray PanCan-d assay
Clinical significance:
- combines 8 serum biomarkers with CA19-9 to generate a risk score
- specificity of 98% & sensitivity of 87% in identifying pancreatic ductal adenocarcinoma among patients at increased genetic or familial risk [1]
General
oncology panel
References
- Hamza Z
Assay Shows Ability to Detect Pancreatic Cancer in People at High Risk.
Serum-based test showed specificity of 98% and sensitivity of 85% for
ID'ing early-stage PDAC.
MedPage Today February 18, 2022
https://www.medpagetoday.com/gastroenterology/pancreaticdiseases/97283
- Brand RE, Persson J, Bratlie SO et al
Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples:
Results of a multiplex biomarker signature validation study.
Clin Transl Gastroenterol. 2022. February 14.
PMID: 35166713
https://journals.lww.com/ctg/Abstract/9900/Detection_of_Early_Stage_Pancreatic_Ductal.26.aspx